Table 1.
Demographic and clinical features of patients with systemic sclerosis and healthy controls.
| Features | Patients | Controls | |
|---|---|---|---|
| Number | 46 | 49 | |
| Age (years) | 46.09 ± 12.70 | 41.90 ± 12.23 | |
| Duration of disease (years) | 7.61 ± 6.13 | ||
| Gender (female/male) | 40/6 | 44/5 | |
| IcSSc/dcSSc, n (%) | 6 (13.04%)/40 (86.96%) | 0 | |
| Organ involvement | |||
| Skin | 30 | 0 | |
| Lung (ILD) | 17 | 0 | |
| Heart (PAH) | 10 | 0 | |
| Renal (history of renal crsis) | 1 | 0 | |
| Gastrointestinal | 20 | 0 | |
| Joint | 5 | 0 | |
| Treatment | |||
| Type of disease | Drug name | Number of patients | |
| Limited cutaneous systematic sclerosis | Methotrexate | 4 | |
| Azatioprin | 1 | ||
| Mycophenolate | 1 | ||
| Diffuse systemic sclerosis | Methotrexate | 6 | |
| Azatioprin | 10 | ||
| Mycophenolate | 14 | ||
| Prednisolone | 1 | ||
| Azatioprin + prednisolone | 7 | ||
| None | 2 | ||